SGLT2 抑制剂需要与利尿剂同时使用,以有效减少间歇性液体保留:DAPA-BODY 试验
Takahiro Masuda1, Maki Asakura-Kinoshita2, Kentaro Oka2
1Division of Nephrology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan. takam@jichi.ac.jp.
概括
将SGLT2抑制剂与利尿剂相结合更有效地减少患者的水分保留. 这种组合疗法降低了间歇性液体和总体水分,而无需过度的血体积损失或氨酸-血管酶-氨系统激活.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- -葡萄糖共运输体2 (SGLT2) 抑制剂可以减少液体体积.
- 将SGLT2抑制剂与利尿剂结合使用可能会增加流体减少.
- 在患有水分保留的患者中,对流体动力学的差异影响尚不清楚.
研究的目的:
- 比较SGLT2抑制剂单一治疗与与利尿剂联合治疗.
- 评估对体液状况和可佩水平的影响.
- 评估对血体积和氨酸- ангиотензин- 阿尔多素系统 (RAAS) 激活的影响.
主要方法:
- 包括患有水分保留症的患者 (ECW/TBW比率>0.400).
- 对比SGLT2抑制剂达帕格利弗洛辛单一治疗与达帕格利弗洛辛+利尿剂6个月的治疗.
- 通过生物阻抗和血清佩测量体液状态.
主要成果:
- 组合疗法显示,细胞外水/全体水 (ECW/TBW),全体水 (TBW) 和间歇性液体的减少更大.
- 在组合组中,血清可佩的增加被抑制.
- 两组之间血压,血体积,宁或阿尔多斯特变化没有显著差异.
结论:
- 结合SGLT2抑制剂和利尿剂的联合治疗在减少间歇性液体保留方面更有效.
- 这种组合可以避免过度的血体积耗尽和RAAS激活.
- 同时使用为管理相关患者群体的液体过载提供了卓越的策略.
相关概念视频
01:22Heart Failure Drugs: Diuretics
807
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
807
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
1.6K
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
1.6K
01:23Dipeptidyl Peptidase 4 Inhibitors
594
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
594
01:16Antihypertensive Drugs: Action of Diuretics
2.2K
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
2.2K
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
2.2K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.2K
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
209
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
209